Clicky

Kintor Pharmaceutical Ltd(9939)

Description: Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the People's Republic of China and internationally. The company's products pipeline include Proxalutamide, a second generation androgen receptor (AR) antagonist for the treatment of metastatic castration-resistant prostate cancer, AR positive breast cancer, and COVID-19; and Pyrilutamide, an AR antagonist for the androgenetic alopecia (AGA) and acne vulgaris treatment. Its products pipeline also comprise ALK-1 antibody for the treatment of metastatic hepatocellular carcinoma (HCC) and various solid tumours; GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris; and PD-L1/TGF-ß, a dual target antibody to treat non-small cell lung cancer, biliary tract cancer, triple negative breast cancer, and HPV-associated tumours. In addition, the company's products pipeline include Detorsertib for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and HCC; and Hedgehog/SMO Inhibitor, an inhibitor of the hedgehog signal transduction pathway to treat blood cancer and basal-cell carcinoma. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.


Keywords: Medicine Biotechnology Cancer Clinical Medicine Organ Systems Breast Cancer Prostate Cancer Non Small Cell Lung Cancer Acne Hair Removal Triple Negative Breast Cancer Acne Vulgaris Androgenetic Alopecia Metastatic Castration Resistant Prostate Cancer Anti Acne Preparations Basal Cell Carcinoma Biliary Tract Cancer Antiandrogen Blood Cancer Metastatic Hepatocellular Carcinoma Metastatic Solid Tumours Solid Tumours Treatment Of Metastatic Castration Resistant Prostate Cancer

Home Page: www.kintor.com.cn

No. 20 Songbei Road
Suzhou, 215123
China
Phone: 86 51 2626 39909


Officers

Name Title
Dr. Youzhi Tong Founder, CEO & Exec. Chairman
Ms. Yan Lu CFO, Joint Company Sec. & Exec. Director
Dr. Qun Lu Chief Technology Officer
Mr. Ma Liandong VP and Head of R&D Institute
Mr. Wai Chiu Wong FCS Joint Company Sec.

Exchange: HK

Country: HK

Currency: Hong Kong Dollar (HK$)

Forward PE: 12.6904
Trailing PE: 0
Price-to-Book MRQ: 4.2233
Price-to-Sales TTM: 135.9484
IPO Date:
Fiscal Year End: December
Full Time Employees: 328
Back to stocks